468 results about "Hepatic disorders" patented technology

The invention belongs to the technical field of biological medicines, and provides application of DRAM1 as a diagnosis and treatment target for resisting non-alcoholic fatty liver disease related hepatocellular carcinoma in preparation of a kit, a carrier and a medicine aiming at the problem of lack of effective treatment targets of NAFLD-related HCC. As a target spot for resisting the non-alcoholic fatty liver disease related hepatocellular carcinoma, the expression level of the DRAM1 in liver tissues of non-alcoholic fatty liver disease related hepatocellular carcinoma patients and mice is increased. According to the application disclosed by the invention, research is developed aiming at the effect of the DRAM1 in the generation and development of NAFLD-related HCC, the analysis of TCGA liver cancer queue data and a GSE164760 data set is taken as an entry point, the influence of the DRAM1 on the diagnosis and prognosis of the liver cancer is comprehensively analyzed, and verification is carried out through a mouse in-vivo experiment, so that a new thought and a new target spot are provided for clinical diagnosis and treatment of the liver cancer.

The invention relates to the field of biological medicine, in particular to application of hispidulin in preparation of a lipid de novo synthesis inhibitor or a metabolism-related fatty liver disease treatment or prevention product. The hispidulin disclosed by the invention has a chemical structure as shown in a formula (I). The hispidulin in the invention reverses liver cell lipid droplet excessive infiltration induced by high-dose fructose in a dose-dependent manner; furthermore, the hispidulin dose-dependent ameliorating obesity signs in HFD-induced MAFLD model mice, including liver weight, body weight, blood lipid level, liver fat content, and insulin resistance, without significantly reducing food intake.

Provided are compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

The present invention discloses the application of a molecular marker methylation level detection reagent for primary hepatocellular carcinoma in the preparation of a detection reagent product, and belongs to the field of gene detection technology. By screening the methylation level of the CpG site in the detected region and its reverse complementary sequence, it is identified whether the target sample is from a primary hepatocellular carcinoma patient. The methylation level of the CpG site in the above region has good sensitivity and specificity for the screening or auxiliary diagnosis of primary hepatocellular carcinoma, and can be used to distinguish samples from patients with primary hepatocellular carcinoma, samples from patients with benign liver diseases (cirrhosis, hepatitis, etc.) and samples from healthy people. The detection reagent and application of the methylation level of the molecular marker can improve the detection rate of early primary hepatocellular carcinoma.

The present application provides a variety of salts of 25HC3S, including crystalline salts of 25HC3S. Provided herein are pharmaceutical formulations of the salts of the invention, and methods of treating or preventing diseases therewith, the diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesterolemia, hypertriglyceridemia, alcoholic fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic conditions, autoimmune conditions, inflammatory conditions, and the like. Nervous system disorders, EB virus related growth, and disorders associated with fat accumulation and inflammation. Methods of making the salts of the present application are also provided.

The invention belongs to the field of active peptides, and particularly relates to application of selenium-rich polypeptide in inhibiting NLRP3 inflammasome-related inflammations and regulating cholesterol transport protection lipid metabolism abnormality, the selenium-rich polypeptide is prepared by chelating Adi-Apo fusion protein as shown in SEQ ID NO: 3 and sodium selenite (Na2SeO3); the selenium peptide chelate has the effects of remarkably reducing the concentration of TC / TG in serum, reducing the liver lipid deposition and inflammation level and reducing the atherosclerotic plaque area proportion through high oxidation resistance and high anti-inflammatory activity, and can be used for treating and / or preventing lipid metabolism disorder diseases such as metabolism-related fatty liver diseases and coronary atherosclerosis.

Pharmaceutical compositions of semaglutide or salts thereof for intranasal administration for the treatment of diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) or neurodegenerative diseases. The method of delivering semaglutide through the intranasal route avoids repeated injections and improves systemic absorption of semaglutide as compared to oral pastilles.

The present disclosure relates to a once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same to induce weight loss in humans suffering from fatty liver disease, where the humans may or may not suffer from other complications, such as type 2 diabetes and / or cardiovascular disease / disorder. The dual agonist of the GLP-1R and the GCGR comprises a peptide product of SEQ ID NO. 1 (pemvidude), and a preparation method of the GLP-1R and GCGR dual agonist.

The invention belongs to the field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating liver depression and spleen deficiency syndrome metabolism-related fatty liver disease, which is prepared from the following raw materials in parts by weight: 8 to 10 parts of ginseng, 10 to 15 parts of radix bupleuri, 10 to 15 parts of radix curcumae, 6 to 9 parts of ginger processed pinellia, 6 to 10 parts of fructus amomi, 10 to 15 parts of rhizoma atractylodis, 10 to 15 parts of poria cocos, 10 to 15 parts of semen hoveniae, 10 to 15 parts of radix rehmanniae, 8 to 10 parts of rhizoma polygoni cuspidati and 6 to 9 parts of lignum dalbergiae odoriferae. The traditional Chinese medicine composition is used for treating the metabolism-related fatty liver diseases from the aspects of liver depression, spleen deficiency and phlegm-blood stasis, starts from the core pathological chain of liver depression, spleen deficiency, phlegm-dampness and blood stasis, has the functions of soothing the liver, tonifying the spleen, resolving dampness, reducing fat and promoting blood circulation to remove meridian obstruction, and is particularly suitable for patients with liver depression, spleen deficiency and metabolism-related fatty liver diseases. Clinical tests prove that the traditional Chinese medicine composition has a good treatment effect on patients with liver depression and spleen deficiency syndrome metabolism-related fatty liver diseases, the total effective rate reaches 94% or above, and the traditional Chinese medicine composition is mild in medicine property, good in safety, stable in curative effect, not prone to relapse and suitable for being taken for a long time.

The present invention relates to a composition for inducing liver disease in a mammal and a mammal with a liver disease induced using the same. The animal model of the present invention has been found to be an excellent animal model in which fatty liver, hepatic fibrosis, and insulin resistance are evenly induced, and which successfully reproduces the progression of a series of severe liver diseases, from hepatitis and excessive fibrogenesis in liver tissue through tissue hardening (cirrhosis) to liver cancer, and reflects the characteristics of each stage with high reliability. Accordingly, the present invention may be useful as a means for developing a therapeutic agent for chronic liver disease as well as studying the molecular and circulatory mechanisms of each stage of liver disease.

The present disclosure provides double stranded oligonucleotides, compositions, and methods relating thereto. The present disclosure encompasses the recognition that structural elements of double stranded oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and / or internucleotidic linkages) or patterns thereof, and / or stereochemistry (e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages), and / or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, Ago2 loading, thermal stability, in vivo stability, delivery to tissues and into cells, etc. The present disclosure also provides methods for treatment of diseases, e.g., hepatic diseases, central nervous system (CNS) diseases, etc., using provided double stranded oligonucleotide compositions, for example, in RNA interference.

The invention discloses a Coprococcus eutaxus strain and an application of the Coprococcus eutaxus strain, and relates to the technical field of probiotics. According to the present invention, the Coprococcus eutactus strain is named as Coprococcus eutactus GZSY125, the preservation number is CGMCC No.66029, the preservation date is March 18, 2025, the preservation classification is named as Coprococcus eutactus, the preservation unit is Guangdong Microbial Culture Collection Center, and the address of the preservation unit is the fifth floor, No. 59 building, No. 100 Courtyard, Xianlie Middle Road, Guangdong Province, the preservation number is CGMCC No.66029, the preservation number is CGMCC No.66029, the preservation date is March 18, 2025, the preservation classification is named as Coprococcus eutactus, and the preservation number is CGMCC No.66029. The invention provides the Coprococcus eutaxus, the Coprococcus eutaxus can be used for remarkably improving liver lipid accumulation, inflammation and fibrosis, has a certain treatment effect on the metabolism-related fatty liver disease (MAFLD), provides a new treatment thought for clinically intervening the MAFLD, and has important clinical significance on the treatment of the MAFLD.

A method for improving gut microbiota population in a subject by administering a composition comprising allulose, erythritol or a combination thereof. A method for increasing one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae by administering a composition comprising allulose, erythritol or a combination thereof. A method for preventing, treating or ameliorating a disease in a subject by administering a composition comprising allulose, erythritol or a combination thereof. The disease may be one or more of metabolic syndrome, obesity, type 2 diabetes, insulin resistance, hyperlipoproteinemia, hyperuricemia, hepatic steatosis, hypercholesterolemia, hypertriglyceridemia, irritable bowel syndrome (IBS), colon cancer, allergy, non-alcoholic fatty liver disease, inflammatory bowel disease, cardiovascular disease, or inflammation. The bacterial population may be the species Anaerostipes hadrus, Blautia obeum, Anaerobutyricum hallii, Eubacterium rectale (Agathobacter rectalis), Eubacterium callanderi, Eubacterium limosum and Eubacterium maltosivorans. A composition comprising allulose, erythritol or a combination thereof and one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae is also provided. The composition may in the form of a food composition.

The invention belongs to the technical field of biological pharmacy, and provides an application of jonquil glucoside in preparation of a medicine for treating a metabolism-related fatty liver disease, and the application is that the jonquil glucoside is applied to preparation of the medicine for treating the metabolism-related fatty liver disease. The treatment effect of the jonquil glycoside on MASLD is evaluated by adopting a method for establishing a fatty liver model through induction of HFD high-fat, high-fructose and high-cholesterol feed. Results show that the jonquil glucoside can reduce the liver weight by inhibiting weight gain, reduce the content of TC and TG in serum, improve the conditions of liver inflammation and fat change, reduce the oxidative stress level of liver tissue and restore SIRT1 protein expression of the liver tissue to achieve the purpose of treating MASLD.

The invention discloses a traditional Chinese medicine composition for preventing and treating metabolism-related fatty liver diseases or metabolic syndromes. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 5-50 parts of sweet wormwood, 3-30 parts of scutellaria baicalensis, 5-50 parts of dandelion, 4-60 parts of platycodon grandiflorum, 5-50 parts of fructus aurantii, 3-80 parts of rhizoma pinelliae preparata, 3-70 parts of fructus amomi, 10-80 parts of stir-fried Chinese yam, 5-80 parts of poria cocos and 3-100 parts of raw coix seeds. The traditional Chinese medicine composition for preventing and treating the metabolism-related fatty liver diseases or the metabolic syndromes is simple in formula, proper in compatibility and mild in medicine property, is used for preventing and treating the metabolism-related fatty liver diseases or the metabolic syndromes, is used for improving liver fatty degeneration and inflammation, blood uric acid, blood fat, blood sugar and blood pressure, assisting weight loss and the like, and is safe to use and remarkable in curative effect.

The invention discloses a traditional Chinese medicine composition for treating fatty liver diseases related to metabolic dysfunction. The traditional Chinese medicine composition is prepared from the following raw material medicines: Qu fructus aurantii, lotus leaves, semen cassiae, gynostemma pentaphylla, rhizoma alismatis, rhodiola rosea, radix salviae miltiorrhizae, pseudo-ginseng and rhizoma atractylodis macrocephalae. The traditional Chinese medicine composition and the traditional Chinese medicine compound preparation disclosed by the invention can improve the blood sugar and blood fat levels of fatty liver diseases related to metabolic dysfunction and improve the metabolic level, are remarkable in clinical curative effect, improve the living quality of patients, have the effects of regulating qi, soothing the liver, tonifying the spleen and removing stasis, slow down liver fibrosis by improving blood sugar and blood fat metabolism, and are quick in curative effect and low in price.

The present invention relates to compounds of Formula A and pharmaceutically acceptable salts thereof, their use in medicine; compositions containing them; processes for their preparation; and intermediates used in such processes. The compounds of the invention are useful for treating, preventing, inhibiting, and ameliorating diseases, disorders, and conditions, such as liver diseases. , for example, fatty liver, non-alcoholic fatty liver disease (NALFD), non-alcoholic steatohepatitis (NASH), non-alcoholic steatohepatitis associated with hepatic fibrosis, non-alcoholic steatohepatitis associated with liver cirrhosis, and non-alcoholic steatohepatitis associated with liver cirrhosis and hepatocellular carcinoma.

The invention discloses a multi-classification risk prediction method and system for liver diseases based on machine learning, and relates to the technical field of biomedicine, and the method comprises the following steps: collecting fatty liver disease diagnosis results and biochemical indexes of a subject to form a training sample set, the method comprises the following steps: screening out biochemical indexes significantly related to fatty liver diseases through single-factor regression analysis, determining potential risk factors, carrying out multicollinearity test on the factors, screening out risk factors, constructing a plurality of machine learning classification models for training, and selecting a model with the best performance as a reference model. The contribution degree of each important risk factor is evaluated and sorted, classification significant factors are determined, the significant factors serve as classification metadata, a plurality of judgment models are trained, input factors are dynamically selected according to contribution values, and finally a fatty liver disease degree classification result is output, so that complex conditions under different sample features and clinical backgrounds are better handled; and the accuracy of prediction results is improved.

The present application discloses different classes of mitochondrial uncoupling compounds having significantly improved pharmacokinetic properties and conventional mitochondrial uncoupling compounds, pharmaceutical compositions containing the compounds and / or prodrugs, and diseases that are useful in the treatment of diseases associated with mitochondrial dysfunction or benefits by modulation of mitochondrial activity. Methods of using the compounds, prodrugs, and pharmaceutical compositions in treatment of diseases, including diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), mitochondrial genetic diseases, neurodegenerative diseases, cancer, autoimmune diseases, and infectious diseases.

Provided herein are peptides and peptide conjugates comprising a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The peptides may be used for blood glucose management and treating conditions such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

The invention discloses an application of costunolide in preparation of a medicine for treating and / or preventing a non-alcoholic fatty liver disease. It is found that costunolide can activate an Nrf2-ARE signal channel of a body, liver cell lipid metabolism abnormality is effectively improved from the molecular level, and meanwhile the pathological influence of oxidative damage on liver tissue is remarkably relieved. Experimental data show that the compound has a remarkable intervention effect on NAFLD, a scientific basis is provided for development of a novel liver disease treatment agent due to the unique dual regulation and control mechanism of the compound, particularly, the compound shows an important development prospect in the field of clinical intervention of metabolism-related liver injury, and an innovative solution is provided for NAFLD lacking a special-effect therapy at present.

Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

The invention discloses an FAM20B protein and application of an FAM20B protein inhibitor in prevention or treatment of glucolipid metabolism related diseases. Specifically, the invention discloses an application of an FAM20B protein and / or an FAM20B gene in regulation and control of liver glycolipid metabolism. The invention also discloses application of the FAM20B inhibitor in improving, preventing or treating liver glycolipid metabolism disorder or glycolipid metabolism related diseases (such as diabetes, metabolism related fatty liver disease MAFLD, obesity and the like). Experiments show that the FAM20B inhibitor can reduce the liver gluconeogenesis level, relieve impairment of glucose tolerance, relieve hyperglycemia of diabetic patients, reduce the fat content of the whole body and the liver, relieve liver lipid deposition, promote energy consumption, reduce food intake, promote fat burning and reduce liver fat accumulation; the compound can be used for preparing medicines for preventing and treating glucose and lipid metabolism disorder or glucose and lipid metabolism related diseases, and has a wide application prospect in the fields of prevention and treatment of metabolism related diseases.

The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating a hepatic porphyria, and related syndromes thereof.

The invention relates to the technical field of biology, and particularly discloses a Meditrraneibacter faeces strain and application of the Meditrraneibacter faeces strain in relieving of metabolism-related fatty liver diseases. The Mediterraneeibacter faeces strain found from faeces of healthy people can be applied to preventing, relieving and / or treating metabolism-related fatty liver diseases, animal experiment results show that hepatic cell fatty degeneration of mice is relieved, hepatic cell balloon-like degeneration is reduced, and hepatic cell liver-like degeneration is reduced. Therefore, the strain can improve liver fatty degeneration and inflammatory response of mice with metabolism-related fatty liver diseases. Moreover, by adopting the strain to interfere with the liver function and lipid metabolism of a mouse with the metabolism-related fatty liver disease, the levels of ALT, AST, TG, CHO and LDL in serum of the mouse with the metabolism-related fatty liver disease can be reduced.

25HC3S choline and crystalline 25HC3S choline are described in the present application. Further disclosed herein are pharmaceutical formulations of 25HC3S choline (e.g., containing crystalline 25HC3S choline) and methods of using the pharmaceutical formulations to treat or prevent diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesteremia, hypertriglyceridemia, and the like. Methods of treating fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic conditions, autoimmune conditions, inflammatory conditions, neurological conditions, Epstein-Barr virus associated growth, and conditions associated with fat accumulation and inflammation are provided. Also provided herein are methods of making 25HC3S, including crystalline 25HC3S choline.

The invention belongs to the field of traditional Chinese medicine compositions, and relates to a liver-clearing, spleen-enlivening and stasis-removing composition for treating non-alcoholic fatty liver disease, the liver-clearing, spleen-enlivening and stasis-removing composition comprises the following raw materials by weight: 10-25 g of oriental wormwood, 20-30 g of tea tree root, 20-30 g of adiantum capillus, 5-15 g of earthworm, 5-15 g of sophora flower, 5-10 g of bamboo shavings, 3-6 g of rhizoma nardostachyos, 3-6 g of lotus plumule, 6-12 g of lucid ganoderma, 10-15 g of roxburgh rose, and 5-15 g of honey-fried licorice root. The composition is used for treating the non-alcoholic fatty liver disease according to the idea of'stasis, phlegm, depression and deficiency 'and the viscera dredging theory, through a viscera connection treatment method of clearing liver and relieving depression, strengthening the spleen and clearing damp, and dredging intestines and removing stagnation, and through combination of medicines directly entering the liver channel for promoting blood circulation and dredging collaterals, breaking blood and removing stasis and medicines for caring healthy qi and strengthening the spleen and tonifying deficiency, the treatment effect is good, the effective rate is as high as 97.83%, and the curative effect is good. The traditional Chinese medicine composition is especially suitable for patients with phlegm-blood stasis type non-alcoholic fatty liver diseases.

The invention belongs to traditional Chinese medicine formula granules, and particularly relates to a preparation process of phlegm-eliminating and blood-activating granules and application of the phlegm-eliminating and blood-activating granules in metabolism-related fatty liver diseases. The granule comprises gynostemma pentaphylla and raw hawthorn which are used as monarch drugs, raw bighead atractylodes rhizome, rhodiola rosea and turmeric which are used as ministerial drugs, and auxiliary materials for preparing the granule. The granules with the formula for eliminating phlegm and activating blood, which are researched and developed by the invention, have the characteristics of stable property, convenience in transportation, carrying, storage and use and the like. The preparation technology is high in production efficiency and has good economic value, and the prepared granules can effectively exert the pesticide effect.

The invention discloses an application of isoquercitrin in preparation of a medicine for improving insulin resistance and diabetes-related liver diseases, and belongs to the technical field of medicines. According to the application, a high-glucose and high-fat diet and streptozotocin combined method is adopted to successfully construct a type 2 diabetes mouse model; experiments find that the isoquercitrin can effectively relieve the symptoms of weight loss and water intake increase of T2DM mice, significantly reduce the fasting blood-glucose level and improve abnormal glucose tolerance; the isoquercitrin can reduce the liver index of a T2DM mouse, relieve fatty degeneration of the liver and repair a liver cell structure; by activating a PI3K / AKT signal channel, the isoquercitrin up-regulates the expression levels of PI3K, p-AKT, p-GSK3 and GLUT4 and down-regulates the expressions of GSK3 and PEPCK at the same time, so that the insulin resistance of T2DM mice is effectively improved, the fatty degeneration of the liver is improved, and the isoquercitrin has a protection or repair effect on liver injury.

The present disclosure relates to compounds that can be useful as inhibitors of PD-1, PD-Ll or the PD-1 / PD-Ll interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including, but not limited to, liver diseases, cancer (for example, hepatocellular carcinoma) and / or viral diseases, such as hepatitis B.